Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Key facts
- Who runs it
- Suzhou Alphamab Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 241 people enrolled
- Started
- 20 Dec 2023
- Ended
- 15 Apr 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Enoxaparin
- KN060 Low
- KN060 Middle
- KN060 Hight
- Record updated
- 17 September 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male or female, aged between 18 and 75 years old (including the cut-off value)
- undergoing unilateral Total Knee Arthroplasty (TKA)
- Voluntarily participate in the study and sign a written informed consent
Who cannot take part
- Acute myocardial infarction or ischemic stroke occurred within 6 months before screening
- There is a high risk of bleeding or abnormal bleeding related indicators:
- Evidence of venous thrombosis, such as the presence of related symptoms or auxiliary tests indicating thrombosis; Or have a history of venous embolic disease
- Presence of malignant tumors or history of malignant tumors
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
The 4 groups in the trial
- EnoxaparinExisting treatment, for comparison
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days post-surgery.
- KN060 Low (post-surgery)Treatment being tested
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 low dose once post-surgery.
Treatment: KN060 Low
- KN060 Middle (post-surgery)Treatment being tested
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 middle dose once post-surgery.
Treatment: KN060 Middle
- KN060 Hight (post-surgery)Treatment being tested
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 hight dose once post-surgery.
Treatment: KN060 Hight
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open, Randomized, Active-comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of Different Doses of KN060 for the Prevention of Venous Thromboembolism in Patients Undergoing Unilateral Total Knee Arthroplasty.
- Record updated
- 17 September 2025